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Cigarette smoking is a risk for sight loss. Its various toxins are known to harm various parts of 
the anatomical parts of the eye. The number of people who smokes continue to increase 
causing a major public health issue which needs addressing. Public awareness is important to 
highlight its impact on health and sight. The healthcare professionals play an important role in 
empowering people to quit the habit. Cigarette quitting does improve health and quality of life.  
Aim 
The aim of this article to explore the association of smoking as a risk factor to sight loss and 
the implication of health promotion as a useful strategy to help individuals feel empowered and 
to give up the habit. 
Introduction and Background.  
Cigarette smoking is a well-recognised major risk factor for a wide range of diseases such as 
cardiovascular, respiratory and malignant diseases.  Many people are unaware that smoking 
also affects vision and can cause blindness despite the presence of valid evidence and public 
health campaigns to quit smoking (RNIB, 2012; Zhu, Lee, Zhuang, Gamst, & Wolfson, 2012; 
Evans, Fletcher, & Wormald,  2005; Kelly, Thornton, & Lyratzopolous,  2004; Solberg, 
Rosner, & Belkin 1998). Smoking can lead to many potential eye disorders including cataract 
and age-related macular diseases (AMD). Cope (2014) and RNIB (2012) identify that smokers 
are five times more likely than non-smokers to develop AMD which is the leading cause of 
blindness. Cigarette smoking is an important factor in the causation of pathogenesis and 
progression of several diseases of the eye. The smoke that is inhaled and the ash particles from 
a lighted cigarette are harmful to the body and the structure of the eye. Smoking is a significant 
yet preventable cause of eye diseases and sight loss (WHO, 2012; Solberg et al., 1998). Public 
awareness and knowledge about smoking, its harmful effect on the eyes and adequate support 
to smokers to quit smoking can maintain eye health (WHO, 2012; Kennedy, Spafford, 
Parkinson, & Fong, 2011). Healthcare professionals must take the initiative in applying health 
promotion strategies to help people to quit the habit to promote and maintain eye health.   
 
This article outlines the structure and function of the eye. It explores the prevalence of sight 
loss amongst smokers, the chemical compounds present in tobacco including their toxic effects 
on sight and the health professionals’ role in health counselling and health promotion. A 
conclusion  summarises  the key areas of the discussion. 
 
Structure and function of the eye 
Smoking does affect various anatomical parts of the eye, thus a brief overview of the structure 
and function of the eye is included. The toxins found in tobacco are known to harm sight.  A 
cross-sectional view of the eye is shown in Figure 1.  
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 Figure 1. Cross-sectional view of the eye 
 
 
(Source: www.moorfields.nhs.net)  
 
The main structures and brief a brief functions of the eye are summarised below. 
The cornea is the anterior transparent outer surface of the eye. It is about 0.5 mm thick and has 
5 distinct layers comprising of epithelium, Bowman’s membrane, stroma, Descemet’s 
membrane and inner endothelial layer. It acts as a protective barrier against pathogens and it 
refracts light rays. It contributes to 75% of the eye’s total focussing power. It bends the 
incoming light onto the lens. Tears provide immunological protection and refractive properties 
to the cornea.  
 
The sclera forms the posterior white outer surface of the eye. It is a tough membrane and its 
thickness is about 1 mm. It gives shape to the eye, and it protects the inner structure of the eye. 
The six extra-ocular muscles blend with it about 5 to 6 mm from the corneal junction and these 
muscles help to move the eyes in various directions. 
 
The iris gives the eye its colour which is genetically determined. It is made up of 3 layers of 
connective tissue and muscle fibres: endothelium, stroma and the epithelium. The main 
function of the iris is to control light entering the eye. In bright light the constrictor muscles of 
the iris contract, thus constricting pupil to prevent excessive light entering the retina. In dim 
light the dilator muscle contracts, thus dilating the pupil to allow more light into the eye. The 
pupil is the opening at the centre of the iris that lets light in the eye. It changes size in response 
to light levels.  
 
The ciliary body is next to the iris and it plays an important part in aqueous production and 
lens accommodation. The choroid lies behind the ciliary body and is pigmented and vascular. 
It absorbs light rays, thus improving visual efficiency. Its small blood vessel nourishes the 
macula and the photoreceptors.  
 
The lens is a transparent structure of about 5 mm thick with a diameter of about 9 mm and is 
situated directly behind the iris made up of proteins called crystallins. The lens focuses light 
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onto the retina. It is flexible and its curvature is controlled by the suspensory ligaments under 
the influence of the parasympathetic nervous system.  
 
The vitreous humour is a clear gel, which fills the centre of the eyes. It is made up largely of 
water, hyaluronic acid and collagen fibrils to give it its consistency. It gives form and shape to 
the eye and helps to keep the retina in place. 
 
The retina is the inner neurosensory layer. It contains 3 layers of nerve cells including the 
outermost layer of sensory photoreceptor cells that capture light rays and convert them into 
electrical impulses which are transmitted by the optic nerve to the brain. There are two types of 
photoreceptors: rods and cones. Each retina comprises of about 125 million rods responsible 
for peripheral vision and function best in dim light. There are about 7 million cones in each eye 
around the macula, and are more densely concentrated in the fovea. Cones are essential for 
vision in bright light and for seeing colours and details.  
 
The retinal pigment epithelium is the outer layer of the retina which nourishes the rods and 
the cones.  
 
The macula is situated at the centre of the retina. It is the focus for incoming light  rays and as 
such is responsible for central vision and the ability to see detail. Its diameter is about 1.5mm. 
The fovea is a small pit of around 0.3 mm near the centre of the macula which contains the 
highest concentration of cone photoreceptors, and has no rod photoreceptors. 
 
The optic nerve is the second cranial nerve that transmits visual information in the form of 
electrical impulses from the retina to the brain. The photoreceptors are not present in the optic 
nerve. The optic nerve head creates a blind spot in the field of vision. This is normally not 
noticed because the vision of one eye overlaps with that of the other eye. 
 
Epidemiology and prevalence of smoking 
There is epidemiological evidence that smoking is a major cause in the pathogenesis and 
progression of several eye diseases and blindness particularly AMD, cataract and Grave's 
ophthalmopathy (Cope 2014). Cigarette smoking has become the most prevalent form of drug 
dependence and there is evidence of serious damage to eye health (NHS England, 2019). 
Tobacco kills 1,500 people a week so helping people to quit when admitted to hospital helps 
them, their families and the taxpayer to save thousands of lives (Selbie, 2019); furthermore, 
non-tobacco users also suffer tobacco-related illnesses by inhaling second-hand smoke and 
coming into contact with the spit of oral smokeless tobacco users or with tobacco leaves during 
farming or manufacturing. Tobacco in any form kills and causes ailments of different forms 
affecting millions of people yearly (WHO, 2016). WHO (2018b) reports the estimated and 
projected prevalence of smoking in all age groups from 2000 to 2015 and 2020 to 2025 
respectively is presented in Table 1.  
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Table 1. Age-specific estimated and projected global prevalence rates 2000–2025 (Source: 
WHO 2018b) 
                    Estimated prevalence (%) Projected prevalence 
(%) 
Age group 
(years) 
2000 2005 2010 2015 2020 2025 
15-24 19.1 17.1 15.7 14.3 13.1 12.3 
25-34 27.0 24.3 21.9 20.2 18.8 17.2 
35-44 32.0 29.0 26.5 24.1 22.0 20.6 
45-54 33.2 30.1 27.4 25.4 23.5 21.5 
55-64 29.6 26.8 24.6 22.7 21.1 19.9 
65-74 24.4 22.1 20.0 18.4 17.3 16.2 
75-84 19.4 17.4 16.0 14.7 13.6 12.7 
≥ 85  15.3 14.0 12.4 11.5 10.7 10.0 
 
Table 1 shows that the prevalence of tobacco use is highest among people aged between 45 –
54 years and that the next five years there will be most likely a consistent reduction in 
smoking. WHO (2018a) further reports that tobacco smoking is one of the biggest public health 
threats globally, killing more than 7 million people each year. More than 6 million of those 
deaths are the result of direct tobacco use while around 890,000 are the result of non-smokers 
being exposed to second-hand smoke.  
 
RNIB (2016) reports that although smoking rate is slowly declining in the UK but around 11 
million people still smoke. Public Health England (2017) report that in 2015 the estimated 
smoking-related cost to the NHS in England amounts to £2.6 billion and they recommend 
innovative measures to support the development of the new Tobacco Control Plan for England. 
The use of smokeless tobacco also poses a substantial problem world-wide (Mehrotra & Sinha, 
2018). Smokeless tobacco is classified as a type of tobacco product that is used by means other 
than smoking such as chewing, sniffing or placing the product between the gum and the cheek 
or lip. Smokeless tobacco products are produced in various forms such as chewing tobacco, 
snuff, and dissolvable tobacco products. It is estimated that around 357 million people use 
smokeless tobacco, which is more prevalent in South-East Asia (Malhotra & Sinha 2018). 
Additionally, many people are not aware that one hour of a shisha smoking session is 
equivalent to smoking 100 cigarettes. The retina of a heavy smoker looks ten years older than 
of a non-smoker (RNIB 2016). Smokeless tobacco such as vaping also contains harmful toxins 
that are injurious to sight and may also induce cancer (Varlet, Farsalinos, Augsburger, Thomas, 
& Jean-Francois, 2015; Pankow et al., 2017).  
 
Chemical compounds in cigarettes and their harmful effects  
The various toxins found in cigarettes contribute to vasoconstriction, reduced oxygen 
availability and chronic inflammation. Smoking is a significant, yet preventable, cause of eye 
diseases. It has been shown to be a risk factor for many common and severe eye diseases such 
as age-related macular degeneration, glaucoma, and cataract, which can lead to irreversible 
blindness (RNIB, 2012). Pipe smokers are less likely to inhale than cigarette smokers as pipes 
produce more side stream smoke (Rodenstein & Stanescu, 1985). Pipe smoking causes more 
harm to the lens due to the condensation of tobacco products into the eyes and also by 
continually raising the lens temperature (Cheng et al., 2000). 
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There are over 4,000 active substances in tobacco smoke and most of these are harmful to 
health (Kennedy et al., 2011). It contains numerous compounds with oxidative properties and 
these may cause cataract, AMD, Graves’ ophthalmopathy and uveitis (Cope, 2014). Table 2 
shows some of the harmful chemicals in cigarettes and their effects on smokers. 
 
Table 2.  Some harmful compounds in tobacco and their effects on smokers 
Compounds in tobacco Effects 
Nicotine  Vasoconstrictor and addiction 
 
Tar Carcinogenic and increases oxidative stress 
 
Nitrosamines Carcinogens and harmful to health 
 
Polycyclic aromatic hydrocarbons Toxic, mutagenic and carcinogenic 
Hydrogen  cyanide Toxic by-product , poisonous substances harmful 
to nervous system, respiratory system, 
cardiovascular system and the thyroid glands 
Formaldehyde Carcinogenic and strong irritant to mucus lining  
Carbon monoxide Colourless and poisonous gas , reduces oxygen 
supply to cells 
Heavy metals and toxic mineral 
elements such as: cadmium, 
aluminium, lead, mercury and arsenic 
Carcinogenic, toxic and poisonous elements 
 
How cigarette smoking affects sight 
 
The chemicals in tobacco reduce the body’s ability to protect itself by increasing the levels of 
oxidative radicals and decreasing the level of antioxidants in the body (Handa, Woo, Wagle, 
Htoon, & Au Eong, 2011). Therefore, the body ageing process is accelerated, including the 
eye. High blood pressure, directly caused by smoking, is a risk factor for macular degeneration 
(Evans et al., 2005). Smoking causes narrowing of the blood vessels in the retina, thus reducing 
the oxygen uptake reaching the photoreceptors in the macula. The cyanide in smoke has a 
detrimental effect on the lens protein, thus it increases the risk of cortical, nuclear and posterior 
subcapsular cataracts at an earlier age. Smokers who smoke 20 or more cigarettes daily are 
twice as likely to develop cataract. It also doubles the risk of advanced diabetic retinopathy in 
diabetic patients because of weak retinal blood capillaries (Kanski & Bowling 2011). Anterior 
ischaemic optic neuropathy is a condition where the blood flow to the optic nerve head is 
reduced, resulting in neuronal damage at an earlier age in smokers (Kelly et al., 2004). Heavy 
smokers have a fourfold increased risk of cystoid macular oedema which results in poor vision 
as well as colour disturbance. Antenatal smoking is associated with poor stereovision and 
squint in the baby due to the toxins present in smoke. Passive smoking inhaled by children can 
alter the tear film composition, thus exacerbating dry eye syndrome and allergic eye conditions 
(Kanski & Bowling 2011).  
 
The fume particles irritate the conjunctiva (Kenawy, Clark, & Votruba, 2008). Nicotine is a 
vasoactive compound which can induce vasospasm of the posterior ciliary arteries, resulting in 
anterior ischemic optic neuropathy. The presence of carbon monoxide may interfere with lipid 
homeostasis, thus increasing platelet aggregation and clotting which may reduce retinal blood 
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flow and visual disturbance. The common eye complications associated with smoking are 
shown in Figure 2. 
Figure 2: Some common eye complications associated with smoking. 
1. Cataract 
 
 
 
 
 
 
Cataract is an opacity of the crystalline lens 
(Watkinson & Seewoodhary, 2008). Several 
studies have highlighted the tobacco-smoking 
associated risk of cataract formation.  
Tobacco smoke contains heavy metals, such as 
cadmium, lead, iron and copper that accumulate in 
the lens and cause damage (Cheng et al., 2000).  
Iron precipitates the release of more toxic oxygen 
free radicals with subsequent oxidative damage.  
Those who smoke 15 cigarettes or more daily are 
up to three times more likely to develop cataract 
as non-smokers which in effect is dose-dependent. 
Lens changes occur due to oxidative damage to 
the lens (Kanski & Bowling 2011).  Smoking is 
associated with nuclear sclerosis which is one of 
the most common types of cataract (RNIB 2012).  
 
Cataract formation causes gradual blurring of 
vision, but deteriorates rapidly in smokers due to 
increased absorption of more ultraviolet and 
visible light rays (Kanski & Bowling 2011). 
Patients complain of glare, difficulties with night 
driving and the appearance of multiple images in 
one eye, floaters, haloes around bright lights and 
inability to see well in sunlight (Watkinson &  
Seewoodhary 2008). Colour disturbance occurs in 
cataract and some patients experience reduced 
sensitivity to contrast.   
 
2. Age-related macular degeneration 
 
 
Right eye- normal retina and macula 
Left eye – showing age-related macular 
degeneration  
 
 
Age related macular degeneration (AMD) is a 
common cause of sight loss. More than half of 
people who are visually impaired in the UK have 
lost their sight due to AMD (Macular Society, 
2017). If a smoker has AMD, the condition will 
progress faster if they continue to smoke. There 
are 2 types of AMD, dry and wet type. The dry 
type is a slow progressive degenerative process 
which leads to cell death and atrophy of the retinal 
pigment epithelium (Riordan-Eva & Whitchner, 
2008).  
 
The wet type is less common (Watkinson, 2014). 
It is aggressive in nature and can lead to severe 
sight loss in weeks or even days (Kanski & 
Bowling, 2011). NICE (2008) states that wet 
AMD occurs faster in smokers than in non-
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smokers.  
 
Smokers are most at risk of AMD and smokers 
who have mutations to the HTRA1 gene are 20 
times more likely to develop AMD than non-
smokers; it is estimated that one third of all AMD 
is the result of a combination of genetics and 
smoking (Macular Society, 2017). The tar in 
cigarette smoke contributes to the formation of 
drusens, which are fatty deposits in the retina. 
Riordan-Eva and Whitchner (2008) identify the 
following early signs of AMD: 
 
 Objects appear to change shape, size or 
colour  
 Objects appear to move or disappear 
 Vision is centrally blurred 
 Lines appear distorted and/wavy  
 Dark spots appear in central vision 
 An area of blindness can block out several 
words at normal reading distance  
 Difficulty seeing objects in bright sunlight 
 Glare 
3. Graves Ophthalmopathy 
 
 
 
 
 
 
 
 
 
Tobacco smoking may have a number of effects 
on the thyroid gland as tobacco ingredients 
competively inhibit iodine uptake and 
organifaction in the gland (Thornton, Kelly, & 
Harrison, 2007; Bertelsen & Hegedus,1994). 
Organifaction is the incorporation of iodine into 
the hormone molecule. Benzpyrene , a major 
constituent of tobacco and the effect of smoking 
on the sympathtic nervous system are also thought 
to affect thyroid function. 
 
The pathogenic mechanism underlying Graves 
disease is thought to be autoimmune. The T 
lymphocytes react with one or more antigens 
shared by the thyroid and orbit resulting in a 
destructive inflammatory response. The disease is 
associated with swelling of the retrobulbar 
muscles and surrounding  fatty tissues within the 
orbit (Cope, 2014).  
 
According to British Thyroid Foundtion (n.d.) 
smokers with Graves' disease are about two times 
more likely to develop thyroid eye disease (TED) 
and heavy smokers are eight times more likely to 
develop TED. Continuing to smoke following 
diagnosis is harmful and  progressive affecting  
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the efficacy of therapy, including radioiodine 
therapy or steroids (Cope, 2014). The clinical 
manifestations of Graves’ Ophthalmopathy are: 
 Upper lid retraction 
 Swelling 
 Redness 
 Conjunctivitis 
 Bulging eyes with blurred vision and 
watery eyes 
 Photophobia 
 Serious risk of vision loss from corneal 
exposure or damage to optic nerve. 
 
4. Dry eyes  
 
 
Active smoking is associated with symptoms of 
dry eyes (Kenawy et al., 2008) 
Smoking tends to reduce tear production and 
causes dry eye symptoms (Cope, 2014). This does 
make contact lens wearing problematic in 
smokers.  
 
Dry eye predisposes the patients to corneal 
dryness, conjunctivitis, corneal infection and 
corneal opacity (Watkinson, 2014).  Health 
education is essential.    
 
Dry causes ocular irritation, burning sensation, 
blurred vision, and discomfort. 
Untreated dry eyes can lead to corneal abrasion, 
corneal infection, corneal scarring, corneal 
perforation and sight loss.  
 
 
Global initiative to reduce tobacco use 
 
The World Health Organisation (WHO) Framework Convention on Tobacco Control 
(WHOFCTC) tobacco control provides a clear roadmap to help countries to reduce the 
prevalence of smoking in both males and females (WHO, 2005b).  This initiative was to 
protect present and future generations from the devastating health, social, environmental and 
economic consequences of tobacco consumption and exposure to tobacco smoke.  In spite of 
the continued presence of the tobacco industry and marketing of tobacco this initiative helped 
move towards the global voluntary target of 30% relative reduction in tobacco use.  Article 20 
of the treaty emphasises to integrate tobacco surveillance programmes into national, regional 
and global health surveillance programmes so that data can be compared and analysed at the 
regional and international levels in order for implement appropriate action to reduce tobacco 
consumption.  
 
The WHO member counties adopted the MPOWER package (Table 2) recommended by WHO 
FCTC (2005a) for the application of smoke reduction measures with the following principles: 
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Table 2: The six key principles of WHO FCTC (2005b) 
1.   Monitor tobacco use and prevention policies (Article 20) 
2.   Protect people from tobacco smoke (Article 8) 
3.   Offer help to quit tobacco use (Article 14) 
4.   Warn about the dangers of tobacco (Articles 11 and 12) 
5.   Enforce bans on tobacco advertising, promotion, and sponsorship  (Article 13) 
6.   Raise taxes on tobacco (Article 6). 
 
 
Health Promotion 
 
Health promotion is a key driver in reducing smoking related health problems including ocular 
conditions. Health professionals need to educate the public about the impact of smoking on eye 
health and sight. By increasing their knowledge about the consequences of smoking and 
smoking cessation strategies, health professionals can encourage and support the smokers who 
want to quit.  All smokers who develop ocular discomfort or sight problems should be 
identified for treatment, health counselling and health promotion.   
 
Yach (2018) emphasises the need for more research to end smoking and its health effects to 
address the impact of reduce the demands for tobacco. It is important to focus on smokers as 
the experience of smoking is multifaceted and deeply personal. Therefore the health 
professionals must reflect on the smokers’ experience, identifying their needs and what they 
want as they try to quit.  Yach (2018) highlights three main categories of experiences and 
challenges of smokers: (1) Physical i.e., intense need and cravings; (2) Behavioural i.e., habit 
and ritual and (3) Emotional i.e., pleasure and calming stress, anger and anxiety.  To help the 
smokers to quit or to reduce smoking health professionals should be aware of: 
 Aware of the unique experiences of smokers, and to assess what support they need. 
 Develop or identify tools to help smokers quit or reduce their consumption. 
 Explore and use funding for research to evaluate risk of cigarette smoking and the effects 
of harmful products. 
 Support innovation for effective products and services to help smokers quit. 
 
Cope (2014) identifies that many smokers tend to deny their habit or significantly under-report 
their cigarette consumption. The health professionals should be meticulous and competent 
when assessing the patients in the care setting. It is important to assess the smokers' knowledge 
of eye health effects of smoking. 
 
The US Department of Health and Human Services (2008, cited in Cope 2014) report that less 
than 3 minutes of counselling by healthcare providers has been shown to have increased quit 
rates by 30%. Counselling can enrich the healthcare professional work with patients to improve 
quit rates and help discourage people from starting to smoke (Rennard & Daughton, 2014).  
 
Active listening and reflection will help the healthcare profession to adopt a humanistic 
perspective of the nature of therapeutic relationships: this involves a recognition of the 
patient’s needs and understanding of his or her life situations, value systems and cultural norms 
from within the client’s frame of reference. Health counselling and health promotion are 
interrelated. Tannahill framework of health promotion is useful when applied effectively. 
Tannahill (2009) introduces three key areas in the framework: (a) health education, (b) health 
prevention and (c) health protection as shown in Figure 3. 
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 Figure 3— The three spheres of Tannahill (2009).Health Promotion model  
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
Health education includes the provision of educational leaflets on smoking and its impact on 
eye health. Kennedy et al (2016) report that health warning labels (HWL) on tobacco products 
is an effective method to educate smokers and non-smokers about the harmful effects of 
tobacco use. The healthcare professional asks smokers about smoking, advises them of the 
dangers of exposure to second hand smoking, provides evidence-based information on how to 
quit and supports them to choose the best pathway when making a decision (Zhu et al., 2012). 
Referring the smokers to smoking health care agencies is helpful as they provide useful 
guidance on cigarette quitting and cessation, e.g. directing the patient to the NHS smoke free 
website (http://smokefree.nhs.uk. cited in  Cope 2014).  The stop smoking support groups 
provide information, advice, encouragement and support to empower smokers through self-
reflection, peer coaching and peer support. Seeking advice from Action on Smoking and 
Health (ASH) is resourceful to provide practical help and advice to smokers. Therefore, 
smokers’ self-efficacy by empowerment is crucial. 
 
Prevention of ill ocular health entails informing people how cessation of smoking can prevent 
eye complications.  Klein and Klein (2008) recommend that changes in lifestyle and healthy 
eating may reduce the prevalence of smoking related nuclear and cortical cataracts. More 
research evidence and consistent data is required to advocate for changes in lifestyle other than 
smoking cessation to prevent discomfort and sight loss. 
 
Cigarette smoking increases the production of free radicals in the body resulting in damage to 
cells; smokers should be advised to incorporate a diet containing vitamins which helps 
neutralise free radicals and prevent tissue damage (Martin, 2018). Therefore, advising on diets 
including vitamins and antioxidants to maintain healthy immune system is crucial to maintain 
ocular health.  
 
Health protection strategy ensures smoking cessation support is available to smokers who 
want to quit and to inform them of the law regarding smoking in public places, e.g. in 
restaurants, clubs, pubs, cinemas in order to protect non-smokers from the dangers of second-
hand smoking. Smoking in confined spaces such as in a car or any enclosed area must be 
avoided to reduce the negative effect of smoking. Non-smokers such as children and pregnant 
women must not be exposed to cigarette toxins to prevent health complications (Public Health 
England, 2015).  
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Conclusions 
 
Smoking is a major public health issue resulting in eye problems that may progress to sight 
loss.  The healthcare professional is in a good position to ask smokers about their smoking 
behaviour, provide relevant information and to help them quit a harmful habit. The smokers 
must be directed to the available resources such as the NHS smokefree website and telephone 
helplines which encourages self management and efficacy of quitting smoking on a permanent 
basis. The health promotion tool provides an excellent guide to empower smokers. 
Collaborative partnership working with relevant agencies is recommended when supporting 
smokers. Although this may not influence every smoker to seek help, it could instigate a 
determination for many smokers to seek advice and make an attempt to stop smoking. 
Cessation of smoking will not only improve the smokers’ eye health, but it will also improve 
their general wellbeing, thus reducing their risk of developing other smoking related health 
problems resulting in a better quality of life. 
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